Targeting von Willebrand factor selectively under inflammatory conditions

Area of Science:

• Biochemistry
• Pharmacology
• Hematology

Background:

• Developing targeted anti-thrombotic therapies that avoid bleeding complications remains a significant challenge.
• Current anticoagulants lack specificity, affecting normal clotting processes.
• Inflammation-induced oxidation activates von Willebrand factor (VWF), presenting a therapeutic target.

Purpose of the Study:

• To investigate lumacaftor's potential as a selective inhibitor of VWF under oxidizing conditions.
• To develop and validate a high-throughput assay for screening VWF inhibitors.

Main Methods:

• Computational screening identified lumacaftor for its potential selective VWF inhibition.
• An enzyme-linked immunosorbent assay (ELISA) was developed to assess VWF binding to platelet glycoprotein Ib α.
• VWF activity was compared under both oxidizing and non-oxidizing conditions.

Main Results:

• The developed ELISA demonstrated lumacaftor's ability to inhibit VWF binding selectively under oxidizing conditions.
• Results support lumacaftor's potential as an anti-thrombotic agent active only during inflammation.
• The assay proves effective for high-throughput screening of VWF inhibitors.

Conclusions:

• Lumacaftor exhibits promising selective anti-VWF activity in the presence of oxidation, mimicking inflammatory states.
• The developed assay offers a robust platform for discovering new anti-thrombotic drugs with improved safety profiles.